San Diego, CA. May 13, 2019 - Epic Sciences, Inc. announced today the launch of a new brand identity, redesigned logo, tagline and website. The new brand changes reflect Epic Sciences’ evolving product portfolio offerings, diverse customer base and expanding global reach.
“Since our inception, Epic Sciences set out with a goal to revolutionize cancer care. Our dedicated team delivered a validated proof-of-concept product with our AR-V7 liquid biopsy test to guide treatment for advanced prostate cancer patients, and we have continued to innovate,” said Lloyd Sanders, president and CEO of Epic Sciences.
With the industry’s most comprehensive technology to view how cells emerge, emit and evolve, the company name was kept, maintaining its all-encompassing focus on the cells and its morphology to guide treatment decisions and predict patient response. The new brand logo, called Radiant ‘e’, is rendered in the shape of a single cell. Its expanding spoke-like structure, with a burst of light emanating from its core, echoes the vitality inherent in Epic Sciences’ daily mission of extending lives.
The new logo and tagline ‘The Power of Clarity’ represents the clarity of data, of process, and of the insights Epic Sciences provides throughout the patient journey. While Epic Sciences offers an expanded portfolio of proprietary diagnostic tests and solutions, the power of clarity is central to the company’s service offerings.
“We are still deeply committed to our mission of extending patient lives by delivering the clarity to guide treatment decisions, and the new brand’s overall visual language, vibrant color palette and imagery focuses on human emotion and the moments worth living for,” said Katherine Atkinson, chief commercial officer at Epic Sciences. “Our new website and brand identity better reflect our market-leading position in providing actionable insights to guide treatment decisions and clearly represents our expertise in not only prostate cancer, but also the comprehensive lifecycle of services we bring to our diverse clients including biopharma, clinicians and academia in drug development.”
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions for men with metastatic castrate-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego.